Top

Gepubliceerd in:

16-01-2018 | Artikel

Medisch gebruik van cannabis en zijn psychoactieve werking: een paradox?

Auteur: Frédérique Bawin

Gepubliceerd in: Verslaving | Uitgave 1/2018

Samenvatting

Cannabis wordt momenteel niet langer uitsluitend gezien als een roesmiddel waar gebruikers high van worden, het wordt tevens steeds vaker erkend als een middel met medische toepassingen. Het feit dat cannabis zowel voor medische doeleinden als in de vrijetijdssfeer wordt gebruikt, zorgt ervoor dat zijn psychoactieve werking een delicate positie inneemt binnen de medische context. Tot op heden is de roesverwekkende werking van cannabis binnen medisch gebruik weinig onderzocht. Aan de hand van de literatuur bekijken de auteurs vanuit verschillende invalshoeken welke plaats de psychoactieve eigenschappen van cannabis binnen de medische context innemen. In dit artikel gaan zij na of een eenzijdige negatieve benadering van de high niet om meer nuancering vraagt. Het is van belang dat de bezorgdheid om de psychoactieve werking van cannabis geen negatieve impact heeft op de ontwikkeling van cannabis en zijn afgeleiden tot volwaardige therapeutische middelen.

vorige artikel Redactioneel

volgende artikel Manipulatie bij drugsscreenings

Vertaling van ‘Relaxed but not stoned’, ondertitel in artikel in online tijdschrift The Conversation (Grimison 2016).

Aggarwal, S. K., Carter, G. T., Sullivan, M. D., ZumBrunnen, C., Morrill, R., & Mayer, J. D. (2009). Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. Journal of Opioid Management, 5(5), 257–286.CrossRefPubMed

Aggarwal, S. K., Carter, G. T., Sullivan, M. D., ZumBrunnen, C., Morrill, R., & Mayer, J. D. (2013). Prospectively surveying health-related quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington State reveals managed chronic illness and debility. American Journal of Hospice and Palliative Medicine, 30(6), 523–531.CrossRefPubMed

Alexander, S. P. (2016). Therapeutic potential of cannabis-related drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 157–166.CrossRefPubMed

Andrzejewski, K., Barbano, R., & Mink, J. (2016). Cannabinoids in the treatment of movement disorders: a systematic review of case series and clinical trials. Basal Ganglia, 6(3), 173–181.CrossRef

Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G. (2007). Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. Journal of Neuroscience, 27(43), 11700–11711.CrossRefPubMed

Becker, H. S. (1974). Consciousness, power and drug effects. Journal of Psychedelic Drugs, 6(1), 67–76.CrossRef

Belle-Isle, L., Walsh, Z., Callaway, R., Lucas, P., Capler, R., Kay, R., & Holtzman, S. (2014). Barriers to access for Canadians who use cannabis for therapeutic purposes. International Journal of Drug Policy, 25(4), 691–699.CrossRefPubMed

Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825.CrossRefPubMedPubMedCentral

Bonn-Miller, M. O., Boden, M. T., Bucossi, M. M., & Babson, K. A. (2014). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. American Journal of Drug and Alcohol Abuse, 40(1), 23–30.CrossRefPubMed

Bottorff, J. L., Johnson, J. L., Moffat, B. M., & Mulvogue, T. (2009). Relief-oriented use of marijuana by teens. Substance Abuse Treatment, Prevention, and Policy, 4(1), 1.CrossRef

Chapkis, W. (2007). Cannabis, consciousness, and healing. Contemporary Justice Review, 10, 443–460.CrossRef

Chapkis, W., & Webb, R. J. (2008). Dying to get high: marijuana as medicine. New York: NYU Press.

Clark, A. J., Ware, M. A., Yazer, E., Murray, T. J., & Lynch, M. E. (2004). Patterns of cannabis use among patients with multiple sclerosis. Neurology, 62(11), 2098–2100.CrossRefPubMed

Coomber, R., Oliver, M., & Morris, C. (2003). Using cannabis therapeutically in the UK: a qualitative analysis. Journal of Drug Issues, 33(2), 325–356.CrossRef

Crowther, S. M., Reynolds, L. A., & Tansey, E. M. (red.). (2010). The medicalization of cannabis. Transcript of a witness seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 24 March 2009. Londen: Trustee of the Wellcome Trust.

Dahl, H., & Frank, V. A. (2011). Medical marijuana: exploring the concept in relation to small scale cannabis growers in Denmark. In T. Decorte, G. Potter & M. Bouchard (red.), World wide weed. Global trends in cannabis cultivation and its control (pag. 116–141). Farnham: Ashgate.

Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., & Wong, M. (2016). Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurology, 15(3), 270–278.CrossRefPubMed

Ebert, T., Zolotov, Y., Eliav, S., Ginzburg, O., Shapira, I., & Magnezi, R. (2015). Assessment of Israeli Physicians’ knowledge, experience and attitudes towards medical cannabis: a pilot study. Israel Medical Association Journal, 17(7), 437.PubMed

El-Alfy, A. T., Ivey, K., Robinson, K., Ahmed, S., Radwan, M., Slade, D., et al. (2010). Antidepressant-like effect of ∆9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacology Biochemistry and Behavior, 95(4), 434–442.CrossRef

Gandhi, S., Vasisth, G., & Kapoor, A. (2017). Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers. Canadian Urological Association Journal, 11(3), 138–142.CrossRef

Green, B. O. B., Kavanagh, D., & Young, R. (2003). Being stoned: a review of self-reported cannabis effects. Drug and Alcohol Review, 22(4), 453–460.CrossRefPubMed

Grella, C. E., Rodriguez, L., & Kim, T. (2014). Patterns of medical marijuana use among individuals sampled from medical marijuana dispensaries in Los Angeles. Journal of Psychoactive Drugs, 46(4), 263–272.CrossRef

Grimison, P. (2016). Could a cannabis pill reduce chemotherapy-induced nausea and vomiting? Here’s how we find out. The conversation. https://theconversation.com/could-a-cannabis-pill-reduce-chemotherapy-induced-nausea-and-vomiting-heres-how-we-find-out-66774 (Gecreëerd: 5 dec 2016). Geraadpleegd op: 17 maart 2017.

Grinspoon, L. (2003). The medical marijuana problem. Journal of Cognitive Liberties, 4, 63–81.

Grotenhermen, F., & Schnelle, M. (2003). Survey on the medical use of cannabis and THC in Germany. Journal of Cannabis Therapeutics, 3(2), 17–40.CrossRef

Growing, L. R., Ali, R. L., Christie, P., & White, J. M. (1998). Therapeutic use of cannabis: clarifying the debate. Drug and Alcohol Review, 17, 445–452.CrossRef

Gruber, A. J., Pope, H. G., & Brown, M. E. (1996). Do patients use marijuana as an antidepressant? Depression, 4(2), 77–80.CrossRefPubMed

Hazekamp, A., Sijrier, P., Verpoorte, R., Bender, J., & Van Bakel, N. (2005). Cannabis uit de apotheek is beter. Pharmaceutisch Weekblad, 140(12), 402–405.

Hazekamp, A., Ware, M. A., Muller-Vahl, K. R., Abrams, D., & Grotenhermen, F. (2013). The medicinal use of cannabis and cannabinoids: an international cross-sectional survey on administration forms. Journal of Psychoactive Drugs, 45(3), 1–12.CrossRef

Holt, M., & Treloar, C. (2008). Pleasure and drugs. International Journal of Drug Policy, 19(5), 349–352.CrossRefPubMed

Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V., & Mechoulam, R. (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 30(10), 515–527.CrossRefPubMed

Keane, H. (2008). Pleasure and discipline in the uses of ritalin. International Journal of Drug Policy, 19(5), 401–409.CrossRefPubMed

Kowal, M. A., Hazekamp, A., & Grotenhermen, F. (2016). Review on clinical studies with cannabis and cannabinoids 2010–2014. Multiple Sclerosis, 11(special issue), 1–18.

Lucas, P. (2012). It can’t hurt to ask; a patient-centered quality of service assessment of health canada’s medical cannabis policy and program. Harm Reduction Journal, 9(2), 1–11.

Malan, T. P., Ibrahim, M. M., Lai, J., Vanderah, T. W., Makriyannis, A., & Porreca, F. (2003). CB 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Current Opinion in Pharmacology, 3(1), 62–67.CrossRefPubMed

McPartland, J. M., & Pruitt, P. L. (1999). Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana. Alternative Therapies in Health and Medicine, 5(4), 57.PubMed

Mechoulam, R. (2017). Cannabis and epilepsy. Epilepsy and Behavior, 70(Pt B), 278–279.CrossRefPubMed

Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64, 21–47.CrossRefPubMed

Moran, T. J. (2010). Just a little bit of history repeating: the California model of marijuana legalization and how it might affect racial and ethnic minorities. Washington and Lee Journal of Civil Rights and Social Justice, 17, 557.

Morgan, C. J., Schafer, G., Freeman, T. P., & Curran, H. V. (2010). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. British Journal of Psychiatry, 197(4), 285–290.CrossRefPubMed

Mosher, C. J., & Akins, S. (2006). Drugs and drug policy: the control of consciousness alteration. Thousand Oaks: SAGE.

Nolf, M. (2004). Medisch gebruik van cannabis: exploratief empirisch onderzoek bij geneesheren. Panoptican, 25, 135–154.

Ogborne, A. C., Smart, R. G., Weber, T., & Birchmore-Timney, C. (2000). Who is Using cannabis as a medicine and why: an exploratory study. Journal of Psychoactive Drugs, 32(4), 435–443.CrossRefPubMed

Pedersen, W. (2015). From badness to illness: medical cannabis and self-diagnosed attention deficit hyperactivity disorder. Addiction Research and Theory, 23(3), 177–186.CrossRef

Pedersen, W., & Sandberg, S. (2013). The medicalisation of revolt: a sociological analysis of medical cannabis users. Sociology of Health and Illness, 35(1), 17–32.CrossRefPubMed

Prentiss, D., Power, R., Balmas, G., Tzuang, G., & Isreaelski, D. M. (2004). Patterns of marijuana use among patients with hiv/aids followed in a public health care setting. Journal of Acquired Immune Deficiency Syndromes, 35(1), 38–45.CrossRefPubMed

Quintero, G. (2009). Rx for a party: a qualitative analysis of recreational pharmaceutical use in a collegiate setting. Journal of American College Health, 58(1), 64–72.CrossRefPubMedPubMedCentral

Ransom, J. (1999). ‘Anslingerian’ politics: the history of anti-marijuana sentiment in federal law and how Harry Anslinger’s anti-marijuana politics continue to prevent the FDA and other medical experts from studying marijuana’s medical utility. Harvard: DASH. Third year paper

Reinarman, C., Nunberg, H., Lanthier, F., & Heddleston, T. (2011). Who are medical marijuana patients? Population characteristics from nine California assessment clinics. Journal of Psychoactive Drugs, 43(2), 129–135.CrossRef

Roitman, P., Mechoulam, R., Cooper-Kazaz, R., & Shalev, A. (2014). Preliminary, open-label, pilot study of add-on oral ∆9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clinical Drug Investigation, 34(8), 587–591.CrossRefPubMed

Russo, E. (2007). The solution to the medicinal cannabis problem. In M. E. Schatman (red.), Ethical issues in chronic pain management (pag. 165–194). New York: Informa Healthcare.

Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.CrossRefPubMedPubMedCentral

Schmitz, A. (2016). Benzodiazepine use, misuse, and abuse: a review. Mental Health Clinician, 6(3), 120–126.CrossRef

Swift, W., Gates, P., & Dillon, P. (2005). Survey of Australians using cannabis for medical purposes. Harm Reduction Journal, 2, 18. https://doi.org/10.1186/1477-7517-2-18.CrossRefPubMedPubMedCentral

Tart, C. T. (1971). On being stoned. Palo Alto: Science and Behavior Books.

Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ, 323(7303), 16.CrossRefPubMedPubMedCentral

United Nations Office on Drugs and Crime (2016). World drug report. Vienna: Author.

Velasco, G., Hernández-Tiedra, S., Dávila, D., & Lorente, M. (2016). The use of cannabinoids as anticancer agents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 259–266.CrossRefPubMed

Walsh, Z., Callaway, R., Belle-Isle, L., Capler, R., Kay, R., Lucas, P., & Holtzman, S. (2013). Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. International Journal of Drug Policy, 24(6), 511–516.CrossRefPubMed

Ware, M. A., Rueda, S., Singer, J., & Kilby, D. (2003). Cannabis use by persons living with hiv/aids: patterns and prevalence of use. Journal of Cannabis: Therapeutics, 3, 3–15.CrossRef

Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., & Collet, J. P. (2010). Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal, 182(14), E694–E701.CrossRefPubMedPubMedCentral

Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., & Schmidlkofer, S. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. JAMA, 313(24), 2456–2473.CrossRefPubMed

Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain, 14(2), 136–148.CrossRefPubMed

Zinberg, N. E. (1984). Drug, set and setting. New Haven: Yale University.

Zuardi, A. W. (2006). History of cannabis as a medicine: a review. Revista Brasileira de Psiquiatría, 28(2), 153–157.CrossRefPubMed

Titel: Medisch gebruik van cannabis en zijn psychoactieve werking: een paradox?
Auteur: Frédérique Bawin
Publicatiedatum: 16-01-2018
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Verslaving / Uitgave 1/2018
Print ISSN: 1574-1842
Elektronisch ISSN: 1875-7073
DOI: https://doi.org/10.1007/s12501-018-0155-0

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 1/2018

Geschiedenis van de Amerikaanse verslavingszorg

Herstelgerichte ‘blended’ cognitieve gedragstherapie voor cliënten met verslavingsproblematiek

Effectiviteit van preventief werken met een lespakket over gamen

Uitgelezen

Manipulatie bij drugsscreenings

Verslaving als ziekte: een eindeloze discussie